Nadir CD 4 + T Cell Count Predicts Response to Subcutaneous Recombinant Interleukin-2

Norman Markowitz, Judith D. Bebchuk, and Donald I. Abrams, for the Terry Beirn Community Program for Clinical Research on AIDS Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan; Coordinating Center for Biometric Research, Division of Biostatistics, University of Minnesota, Minneapolis; and Positive Health Program, San Francisco General Hospital, University of California, San Francisco

[1]  C. Hallahan,et al.  Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.

[2]  R. Davey,et al.  Randomized, Open‐Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin‐2 on Viral Burden in Patients With HIV‐1 Infection and CD4+ Cell Counts of ≥300/mm3: CPCRA 059 , 2002, Journal of acquired immune deficiency syndromes.

[3]  D. Cooper,et al.  The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy , 2002, AIDS.

[4]  A. Mirmohammadsadegh,et al.  Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy , 2002, AIDS.

[5]  M. Magnani,et al.  Exogenous Interleukin-2 Administration Corrects the Cell Cycle Perturbation of Lymphocytes from Human Immunodeficiency Virus-Infected Individuals , 2001, Journal of Virology.

[6]  S. Emery,et al.  Immunomodulators as adjunctive therapy for HIV-1 infection. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  C. Hallahan,et al.  CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients , 2001, AIDS.

[8]  A. Lazzarin,et al.  Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. , 2001, The Journal of infectious diseases.

[9]  J. Vierling,et al.  Viral, host and interferon‐related factors modulating the effect of interferon therapy for hepatitis C virus infection , 2001, Journal of viral hepatitis.

[10]  R. Lempicki,et al.  Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Hoofnagle,et al.  Hepatitis C in African Americans: summary of a workshop. , 2000, Gastroenterology.

[12]  J. Kovacs,et al.  Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. , 2000, The Journal of infectious diseases.

[13]  J. Kahn,et al.  Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.

[14]  R. Davey,et al.  A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. , 2000, The Journal of infectious diseases.

[15]  M. Juan,et al.  Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with , 1999, The Journal of infectious diseases.

[16]  É. Oksenhendler,et al.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial , 1999, The Lancet.

[17]  G. Stewart,et al.  Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. , 1998, The Journal of infectious diseases.

[18]  J. Bartlett,et al.  Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. , 1998, The Journal of infectious diseases.

[19]  J. Metcalf,et al.  Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. , 1997, The Journal of infectious diseases.

[20]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[21]  J. Metcalf,et al.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. , 1995, The New England journal of medicine.